Loading...
•
Mar 30
Revvity Q1 2025 Earnings Report
Revvity reported solid financial results with revenue and earnings exceeding expectations.
Key Takeaways
Revvity delivered strong Q1 2025 results, surpassing revenue and earnings forecasts, driven by resilience across its Life Sciences and Diagnostics businesses.
Revenue reached $665 million, reflecting 2% reported and 4% organic growth.
Adjusted EPS came in at $1.01, slightly above the prior year's $0.98.
GAAP Net Income totaled $42 million, up from $26 million a year earlier.
The company reaffirmed its full-year organic growth and adjusted EPS guidance.
Revvity
Revvity
Revvity Revenue by Segment
Revenue by Segment
Life Sciences Revenue
CapyFin.comDiagnostics Revenue
CapyFin.com Forward Guidance
Revvity raised its full-year revenue guidance and reaffirmed its 3-5% organic growth and $4.90-$5.00 adjusted EPS targets.
Positive Outlook
- Revenue guidance increased to $2.83-$2.87 billion due to favorable currency rates.
- Organic growth outlook reaffirmed at 3-5%.
- Adjusted EPS guidance reaffirmed at $4.90-$5.00.
- Expectations of continued strong cash flow generation.
- Strategic positioning in high-growth healthcare markets.
Challenges Ahead
- Macroeconomic uncertainties could impact future results.
- Currency fluctuations remain a potential headwind.
- Potential supply chain disruptions.
- Competitive pressures in diagnostics and life sciences markets.
- Ongoing litigation and regulatory risks.